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ABSTRACT
Tyrosine kinase (TK) fusions are attractive drug
targets in cancers. However, rapid identification of
these lesions has been hampered by experimental
limitations. Our in silico analysis of known cancer-
derived TK fusions revealed that most breakpoints
occur within a defined region upstream of a
conserved GXGXXG kinase motif. We therefore
designed a novel DNA-based targeted sequencing
approach to screen systematically for fusions
within the 90 human TKs; it should detect 92% of
known TK fusions. We deliberately paired
‘in-solution’ DNA capture with 454 sequencing to
minimize starting material requirements, take ad-
vantage of long sequence reads, and facilitate
mapping of fusions. To validate this platform, we
analyzed genomic DNA from thyroid cancer cells
(TPC-1) and leukemia cells (KG-1) with fusions
known only at the mRNA level. We readily identified
for the first time the genomic fusion sequences of
CCDC6-RET in TPC-1 cells and FGFR1OP2-FGFR1
in KG-1 cells. These data demonstrate the feasibility
of this approach to identify TK fusions across
multiple human cancers in a high-throughput,
unbiased manner. This method is distinct from
other similar efforts, because it focuses specifically
on targets with therapeutic potential, uses only
1.5mg of DNA, and circumvents the need for
complex computational sequence analysis.
INTRODUCTION
Tyrosine kinases (TKs) are tightly regulated signaling
enzymes that control multiple cellular processes. When
TK signaling becomes deregulated due to mutations or
rearrangements involving the kinase domain, the resultant
sustained activity can lead to cancer. Because constitutive
kinase activity can also be required for tumor mainten-
ance, aberrant TKs serve as attractive therapeutic targets
(1). The best example of this concept involves the
BCR-ABL (BCR - breakpoint cluster region gene;
ABL - Abelson murine leukemia viral oncogene
homolog 1 gene) TK fusion protein in patients with
chronic myelogenous leukemia (CML) (2). As a conse-
quence of the fusion, the ABL kinase is constitutively
activated (3,4). CML cells are dependent upon signaling
from BCR-ABL and die upon treatment with the kinase
inhibitor, imatinib (Gleevec). Clinically, the drug has
revolutionized treatment of the disease.
Thus far, only a limited number of TK fusions have
been found in cancers. The majority of TK fusions have
been identiﬁed in hematopoietic malignancies as opposed
to solid tumors, because the latter are difﬁcult to karyo-
type, harbor multiple genomic aberrations, and are often
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exist in epithelial cancers. TK fusions involving RET,
NTRK1, -3, and the serine/threonine kinase, BRAF,
have been found in radiation-induced thyroid cancers
(6–8). Recently, a subset of non-small cell lung cancers
(NSCLCs) was discovered to harbor gain-of-function
ALK and ROS fusions (9–11). Importantly, only 2 years
later, an ALK inhibitor has already demonstrated
promising activity in patients with EML4-ALK-
fusion-positive lung tumors (12). However, the identiﬁca-
tion of these fusions involved highly laborious techniques
not amenable to rapid screening.
The recent application of high throughput next gener-
ation sequencing technologies to whole genomes and
whole transcriptomes has facilitated the discovery of
multiple translocation events in cancer cells (13–19).
These efforts have been enhanced further by re-sequencing
of selectively captured regions of interest (20). Capture
technologies utilize complementary oligonucleotide
‘baits’ either immobilized on a chip (solid capture) or
in-solution (liquid capture) (21–24). Traditionally, chip
based arrays have been coupled with long read 454
sequencing (21,23,24), while ‘in-solution’ capture was
has been paired with short read sequencing (i.e. Illumina
GA and AB SOLiD) (22). However, these methods require
large amounts of starting material and generate vast
numbers of sequences. Furthermore, these methods have
not focused speciﬁcally on identifying TK fusions.
Here, we present the development of a ‘rationally
designed’ DNA capture strategy that overcomes many of
the limitations of current fusion discovery platforms. Our
strategy focuses speciﬁcally on the discovery of novel TK
fusions because of their clinical signiﬁcance and inherent
druggability. We hypothesized that tumors contain as yet
unidentiﬁed TK fusions whose discovery has been
hindered by experimental limitations. In contrast to
other targeted approaches, our design was based upon
unique conserved genomic properties of existing TK
fusions. Importantly, our capture-sequence approach is
feasible, rapid, and requires minimal amounts of starting
tumor cell DNA, making it amenable for high-throughput
screens to identify systematically TK fusions in any cancer.
MATERIALS AND METHODS
Genomic coordinate mapping
The nucleotides encoding the GXGXXG motif for all
90 TK kinases (25) and four serine/threonine kinases
(BRAF, AKT-1, -2, -3) were mapped using MapBack
(hg18), a locally created database that maps protein
residues to corresponding genomic coordinates
(http://cbio.mskcc.org/Public/products/human_mapped/
Mapback; A. Lash and C. Byrne, manuscript in prepar-
ation). From these regions, genomic coordinates for the
three preceding introns and the two preceding exons were
mapped using ENSEMBL (hg18; http://www.ensembl.
org). All exons/introns were labeled according to
ENSEMBL numbering. In cases where the GXGXXG
motif was encoded by more than one exon, only the ﬁrst
exon was included in capture, as breaks are likely to occur
upstream of this motif. For ABL1, capture included intron
1-2 to exon 4 (GXGXXG motif), and for ROS1, capture
included intron 31-32 to exon 36 (GXGXXG motif). An
extra exon and intron upstream of the target region were
also included for ABL2. Coordinates were submitted to
Agilent Technologies (Santa Clara, CA, USA) for custom
bait design. Repetitive elements, as identiﬁed by the
UCSC genome browser (26) (http://www.genome.ucsc.
edu), were excluded from bait design.
Samples and cell lines
The human cell lines KG-1 and TPC-1 have been
characterized previously (27,28). KG-1 cells and TPC-1
cells were kindly provided by R. Levine and J. Fagin
(MSKCC), respectively. KG-1 cells were cultured in
RPMI media (American Type Tissue Collection, ATCC)
supplemented with 10% fetal bovine serum (Gemini Bio
Products) and pen-strep solution (Gemini Bio Products;
ﬁnal concentration 100U/ml penicillin, 100mg/ml strepto-
mycin). TPC-1 cells were cultured in Dulbecco’s Modiﬁed
Eagle Medium (DMEM) supplemented with glucose
(4.5g/l), 5% fetal bovine serum, pen-strep solution
(ﬁnal concentration 100U/ml penicillin, 100mg/ml
streptomycin) and 2mM glutamine. All cells were grown
in a humidiﬁed incubator with 5% CO2 at 37 C.
DNA capture and 454 sequencing
Genomic DNA from all samples was extracted using
standard phenol extraction protocols. 1.5mg was sheared
with a Roche Nebulizer to 300–500bp fragments.
Fragment size was conﬁrmed on a BioAnalyser, DNA
7500 assay (Agilent). 454 adaptors (Roche) were ligated
according to the manufacturer’s instructions. Ligated
products were size selected on an agarose gel, puriﬁed
using the AMpure kit (Agencourt), and PCR ampliﬁed
for 15 cycles. The PCR products were puriﬁed with a
mini-elute PCR puriﬁcation kit (QIAGEN). Capture was
performed at Agilent Technologies (Santa Clara, CA,
USA) using their SureSelect Target Enrichment System.
Subsequently, 2–4ml of eluted single stranded DNA was
used for emulsion PCR with emPCRkit I (Roche).
Approximately 300000 beads/sample/run were used for
sequencing on a 454 FLX sequencer (Roche).
Computational analysis
Two independent BLAT-based methods were used for
454 sequence analysis. The ﬁrst method aligned
454 reads to a custom library of known genes derived
from BLAT (29). Only TK-containing sequences (and
BRAF and AKT-1,-2,-3-containing sequences) were con-
sidered for further evaluation (Supplementary Figure S2).
To minimize recovery of repetitive elements and low com-
plexity sequences, candidate fusion sequences then had to
meet the following criteria: (i) the entire length of the
sequence had to map to  3 targets within the genome;
(ii) the sequence overlap between the targets could not
exceed 5 bps and (iii) any sequence gaps between the
targets could not exceed 5 bps.
The second method mapped the 454 reads to the entire
human genome using BLAT and considered only those
6986 Nucleic Acids Research, 2010, Vol.38, No. 20reads that hit one kinase target and one other region in
order along the query sequence. The candidate sequences
in the high-scoring segment pairs (HSPs) of the BLAT
output then had to meet the following criteria: (i) the
distance between the targets could not exceed 5 bps;
(ii) no more than one mismatch was allowed, and gaps
were  2 bps; (iii) alignment to the two targets had to
account for  95% of the query sequence; and (iv) no
more than 5 bases could be removed from either end of
the sequence.
Additionally, sequences from candidate fusions
identiﬁed by either method had to be recovered from at
least two independent 454 sequences. A combined list of
TK fusion candidates was generated from sequences that
met these criteria. These sequences were then aligned back
to the entire genome using BLAT, and those with  98%
identity to a single repetitive element were eliminated. The
remaining candidate fusion sequences were validated by
PCR using fusion point-spanning primers and appropriate
genomic DNA. Upon PCR conﬁrmation, the genomic
fusion sequence was queried against all the 454 reads
from the same sample to ﬁnd additional fusion sequences
that may have been missed by automated methods. In
particular, this step allowed us to recover fragments
where the length of sequence from one fusion partner
was <25 bps, the minimum length required for BLAT
searches.
Mapping of 454 sequences and enrichment calculation
454 sequences were mapped initially to the human genome
(hg18) using BLAT (29) with parameters that would allow
for partial mapping of reads, as would be the case if
fusions were present. Average read length was determined
from all reads so as not to exclude any fusion sequences
mapping to multiple targets.
The capture efﬁciency was calculated from the fraction
of mapped sequences that overlapped with bait target
regions. To put this number in proper context, and to
account for the small portion of the genome used for
capture, we computed a ‘normalized’ enrichment factor
deﬁned as:
Enrichment ¼
No: of reads hitting targets=total number of reads
total size of targets in base pairs=total size
of genomeðin bpÞ
This equation corrects for cases where a small genomic
region was targeted with baits.
The mapping outputs from each sample were then
converted to and loaded as .bed ﬁles into the UCSC
genome browser (see Supplementary Table S3 for
sample barcodes) in addition to the genomic coordinates
for each of the custom baits provided by Agilent
Technologies. We also loaded the target sequences used
for bait design as reference. Genomic coordinates for the
individual baits are available upon request. Fusion se-
quences were mapped to the region with highest
homology. The mapping of the sequences and co-
ordinates across the entire genome is publicly available
at: http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg18&
hgt.customText=http://cbio.mskcc.org/ socci/JC/
groupA.bed.gz.
Fusion point conﬁrmation
PCR ampliﬁcation of the candidate fusion genomic break-
points and wild-type sequences was performed with
M13-tagged primers (Supplementary Table S3) using
HotStarTaq Master Mix (QIAGEN) and standard
cycling conditions (95 C for 15m, 35 cycles of 94 C for
30s, 60 C for 30s, 72 C 1min and ﬁnal extension at 72 C
for 10m). Normal male DNA (Promega) was used as a
negative control. PCR products were separated by agarose
gel electrophoresis. Excess primers and dNTPs were
removed with ExoSAP-IT (USB Corporation), as per
the manufacturer’s instructions, prior to direct
dideoxynucleotide sequencing at the Vanderbilt DNA
Sequencing Facility.
50-Rapid ampliﬁcation of cDNA ends
Total RNA was extracted from KG-1 cells with TriZol
reagent (Invitrogen). Extracted RNA was treated with
DNase I (Sigma-Aldrich) and precipitated using
standard protocols. Rapid ampliﬁcation of cDNA ends
(RACE) was done with a 50-RACE system (Invitrogen),
as per the manufacturer’s instructions. Five micrograms of
RNA was used for the initial cDNA reaction with
FGFR1.GSP1 (ACGGTTGGGTTTGTCCTTGT).
Following dC-tailing, the cDNA was ampliﬁed with
FGFR1.GSP2 (TCAGAGACCCCTGCTAGCAT) and
the provided abridged anchor primer. PCR products
were conﬁrmed by agarose gel electrophoresis, and
cloned into pCR.II-TOPO using a TOPO-TA cloning kit
(Invitrogen). The presence of a PCR product insert was
conﬁrmed by Eco-RI digestion (New England BioLabs),
and inserts were sequenced using the T7 tag within the
plasmid (Vanderbilt DNA Sequencing Facility).
Long-range PCR
Long-range PCR was performed with the LongRange
PCR Kit (QIAGEN), as per the manufacturer’s instruc-
tions. An FGFR1OP2-F primer (AGATGATCCGGGTA
TAATAA) within exon 4 and an FGFR1-R primer (AGA
AGAACCCCAGAGTTCAT) within exon 10 were used
to amplify the genomic fusion sequence. The products
were separated by agarose gel electrophoresis, and excess
dNTPs and primers were removed with ExoSAP-IT (USB
Corporation). The product was sequenced in steps using
the primers FGFR1.fus-R1 (TCCAAAGACCATGGTA
GGCC), FGFR1.fus-R2 (CACCTCTTCCAGCTTGAC
AT), FGFR1.fus-R3 (CGGTCATTCTTGCACACACC)
and FGFR1.fus-R4 (ATGGGAGGGACCTGGTAG
GA) at the Vanderbilt DNA Sequencing Facility.
RESULTS
In silico analysis of TK fusions
Using an in silico approach, we analyzed the protein se-
quences from known cancer-derived TK rearrangements
Nucleic Acids Research, 2010, Vol.38, No. 20 6987(n=59; Supplementary Table S1). Strikingly, all TK al-
terations identiﬁed to date contain an intact conserved
GXGXXG motif (Figure 1A), which is essential for
kinase activity (30). We also found that fusion points
within the TK protein sequence usually occur within
 200 amino acids upstream of this motif, with few excep-
tions (e.g. JAK2 and ABL1).
This result prompted us to examine corresponding
genomic fusion points at the DNA level. Although fewer
DNA fusion sequences have been mapped, these also
occur within a deﬁned region (Figure 1B). In most in-
stances, the GXGXXG motif is encoded by a single
exon. The distance from the GXGXXG motif to the
fusion point was variable due to the differences in intron
and exon sizes. However, 80% of the TK fusions we
analyzed had a fusion point within three introns
upstream from the GXGXXG-encoding exon
(Figure 1C). Breaks within ABL1, -2 and ROS occurred
outside of this pattern. Assuming that novel TK fusions
will follow a similar pattern, it should be possible to search
systematically in a non-biased manner for fusions
involving breaks within these regions in any of the
90 TKs in the human genome (25) using genomic DNA.
Strategy for systematic discovery of TK fusions
Our strategy for TK fusion discovery employs existing
‘DNA capture’ technology (21–23) followed by
‘next-generation’ sequencing (31) of recovered sequences.
SureSelect technology (Agilent) captures speciﬁc DNA
regions of interest (‘catch’) using 120-mer RNA ‘baits’
in-solution, allowing for enrichment of target sequences
compared to unselected DNA (22). For this project, we
paired SureSelect Target Enrichment technology with
454 sequencing (Figure 2) because the amount of
starting template needed for SureSelect is the least
(1.5mg) of any of the existing capture platforms, and the
454 platform delivers the longest read-lengths per
sequence among next-generation sequencing platforms.
To date, pairing ‘in-solution’ capture with long read se-
quencers (e.g. 454) has not been reported. We reasoned
that longer reads would allow us to directly ﬁnd fusion
points without the need for intensive bioinformatic
mapping algorithms.
To capture genomic regions of interest, we mapped the
nucleotides encoding the GXGXXG motif for all 90 TKs
in the human genome (Supplementary Table S2). We also
included AKT-1, -2 and -3, and BRAF; these
serine-threonine kinases have been implicated in cancer,
and BRAF is rearranged in a subset of thyroid cancers
(32). These regions were extended to include the entire
GXGXXG-encoding exon, two preceding exons, and
three preceding introns (Figure 1C). For TKs shown re-
peatedly to break outside this pattern (e.g. ABL1, -2 and
ROS), the capture region was increased to include those
areas where previous breaks had been observed. Based on
our in silico analysis, capture of these mapped regions
should detect 92% of known fusion points. The collective
genomic coordinates were then submitted for custom bait
design with 2x coverage for all capture regions.
Coordinates for AATK were inadvertently left out of
bait design. This focused capture strategy targets the
regions where fusion points are most likely to occur
and should reduce recovery of ‘diluting’ wild-type se-
quences. To decrease the amount of low complexity
DNA, repeating regions (as identiﬁed by the UCSC
genome browser, hg18) were excluded from bait design.
Bait tiling averaged 73% across all targets (range: 34–
100%, excluding AATK; Supplementary Table S2).
Therefore, evenness of bait coverage across the target
regions was dependent on the presence or absence of re-
petitive elements.
Analysis of enriched sequences following capture
The assay was validated using DNA from two human
cancer cell lines with known TK fusions: the thyroid pap-
illary carcinoma cell line, TPC-1, known to harbor a
CCDC6-RET fusion (27), and the acute myeloid
leukemia cell line, KG-1, known to contain an
FGFR1OP2-FGFR1 fusion (28). For both cell lines,
fusions had been previously identiﬁed only at the
mRNA level. Genomic DNA was sheared and ligated to
454 sequencing adaptors (Figure 2). The length of the
sheared DNA (300–500nt) was signiﬁcantly longer than
the baits (120-mers), allowing for capture of fusion se-
quences with only a short TK-containing portion.
Following DNA capture,  60000–100000 reads per
sample were generated using the 454 FLX platform
(Table 1). In total, the length of recovered reads
averaged 193bp (Supplementary Figure S1), and se-
quences corresponding to TK ‘baited’ regions were
enriched  776-fold, indicating the efﬁciency of our
capture. Twenty two per cent of the ‘catch’ mapped to
bait regions, and the average enrichment across all
kinases ranged from 80- to 3180-fold (excluding AATK;
Supplementary Table S2). To visualize the ‘bait’ and
‘catch’ coverage across the genome, these ﬁles were
loaded as custom tracks into the UCSC genome browser
(publicly available, ‘Materials and Methods’ section).
The average bait coverage for TPC-1 sequences was
0.90x (range 0–17.0x) and 1.51x for KG-1 sequences
(range 0–29.4x). Of the 13972 baits used for capture,
2552 (18.3%) were covered by >2 TPC-1 sequences.
3697 baits (26.5%) had >2x coverage by KG-1
sequences. The differences in coverage between the two
cell lines can be explained partly by the greater number
of sequences recovered from capture of KG-1 DNA
(Table 1).
The recovered sequences were analyzed for fusions
using two novel independently derived computational al-
gorithms (Supplementary Figure S2). Both BLAT-based
methods separated target-containing sequences from
non-target containing sequences as an initial ﬁlter. This
was achieved by aligning the sequences to a library of
known human genes or the entire human genome. Each
algorithm generated a list of potential candidate fusions
from the target-containing sequences using slightly differ-
ent alignment and stringency criteria (‘Materials and
Methods’ section). An entire sequence read had to be com-
pletely ‘mappable’ with small (2–5bp) gaps or overlapping
regions. To reduce the number of false positives, fusion
6988 Nucleic Acids Research, 2010, Vol.38, No. 20Figure 1. Conserved fusion point patterns from cancer-derived TK fusions. (A) All TK fusions identiﬁed to date contain an intact GXGXXG motif
essential for kinase function. Fusion points occur within a deﬁned region ( 200 amino acids) upstream of this motif, with few exceptions (e.g. JAK2,
ABL1). Fusion points are usually conserved within the same kinase, regardless of the upstream partner. (B) At the genomic level, the GXGXXG
motif is usually encoded by a single exon (asterisked). Genomic breaks usually occur within the three introns preceding the GXGXXG-encoding
exon. The GXGXXG-encoding exon for ABL1 (exon 4) is not pictured. The TK order is the same as that in (A). Green arrows indicate known
genomic fusion points; black arrows indicate suspected fusion points that have not been mapped at the genomic level. (C) Based on this analysis
(A and B), we targeted the region upstream of the GXGXXG-encoding exon for DNA capture. The genomic coordinates for the
GXGXXG-encoding exon, the two preceding exons, and the three preceding introns were mapped for all 90 human TKs. Four serine/threonine
kinases (BRAF, AKT-1, -2, -3) were also included. For kinases that repeatedly break outside this pattern (e.g. ROS1, ABL1), additional regions were
included in the capture design.
Nucleic Acids Research, 2010, Vol.38, No. 20 6989sequences also had to be recovered at least twice.
Both methods produced similar results, and a combined
list of fusion candidates was compiled for each sample
(Supplementary Table S3).
Identiﬁcation of the CCDC6-RET genomic fusion
sequence in TPC-1 cells
Approximately 60000 reads were recovered from captured
TPC-1 DNA (Table 1). Around 22% of sequences
mapped to baited target regions, translating to a
772-fold enrichment of kinase-containing DNA over
other genomic sequences. Computational analyses
identiﬁed 12 potential kinase rearrangements
(Supplementary Table S3), including a fusion sequence
recovered twice that mapped to intronic regions from
CCDC6 and RET (Figure 3A). This CCDC6-RET fusion
was the only candidate validated by PCR and direct
sequencing (Figure 3B–D). The 12nt sequence surround-
ing the fusion point was subsequently queried against the
entire pool of TPC-1 454 sequences. One additional fusion
sequence was found; it was likely missed by the automated
algorithms, because it contained only a short (15bp)
fragment of CCDC6. In total, all three sequences con-
tained the same fusion point (Figure 3A). These data dem-
onstrate the feasibility of our platform to detect TK
fusions from genomic DNA.
We next investigated the ‘bait’ and ‘catch’ coverage
across RET kinase by simultaneously mapping these co-
ordinates within the UCSC browser (26) (Figure 3E).
Approximately 97% of RET was covered with baits, and
RET-containing sequences covered most of the target
region (1053-fold enrichment; 3.6-fold average coverage;
Supplementary Table S2). Areas with few or no recovered
sequences contained mostly repetitive regions, which did
not have corresponding baits. The CCDC6-RET fusion
sequences could have been captured by four separate
baits within intron 11-12 of RET.
Figure 2. Schematic of experimental workﬂow. 454 depiction adapted from Margulies et al. 2005.
Table 1. 454 sequencing and bait enrichment statistics
Sample TK status Total
number
of reads
Number
of bait hits
Hit (%) Fold
enrichment
TPC-1 CCDC6-RET 58216 12564 22 772.32
KG-1 FGFR1OP2-FGFR1 95393 21161 22 793.84
The total number of mappable reads was calculated for each sample.
These reads were then mapped against the genomic coordinates of the
custom designed baits within each target region (Figure 1C) to
determine how many sequences ‘hit’ the baits. Because repeating
regions were excluded from bait design, the genomic regions against
which baits were designed were smaller than the target regions origin-
ally outlined. The fold enrichment represents the increased probability
of recovering kinase sequences after capture compared to their recovery
by chance alone among sequences from the entire genome
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FGFR1OP2-FGFR1 in KG-1 cells
Reads recovered from captured KG-1 DNA were enriched
 794-fold for TK-containing sequences (Table 1). From
the 22% of sequences that mapped to baited target
regions, we identiﬁed 30 potential TK alterations, one of
which involved two non-contiguous portions of FGFR1
(Figure 4A, Supplementary Table S3). Only the fusion
involving FGFR1 was conﬁrmed by PCR using fusion-
speciﬁc primers and direct sequencing of the PCR
products (Figure 4B and C). No additional reads were
found after querying the FGFR1 fusion sequence against
Figure 3. Identiﬁcation of the genomic fusion point of CCDC6-RET in TPC-1 thyroid cancer cells. (A) Using the capture-sequence method, three
different candidate sequences (labeled with ‘FU61UDT04’ barcodes) were recovered that mapped to the intron between RET exons 11 and 12 (blue)
and the intron between CCDC6 exons 1 and 2 (red). (B) PCR using primers speciﬁc for wild-type RET, wild-type CCDC6, and the identiﬁed
CCDC6-RET fusion were used to conﬁrm presence of the fusion only in TPC-1 cells. (C) Direct sequencing chromatograms of the PCR product
containing the fusion. The corresponding 12nt are underlined in A. (D) Schematic of the genomic structure of the fusion point. The
GXGXXG-encoding exon is marked with an asterisk. (E) 454 sequences from captured TPC-1 DNA (black) and the custom 120-mer baits
(green) designed for capture were mapped to the genome. The target capture region for RET (red) is shown as a reference. The location of the
gene within the chromosome is denoted by a vertical red bar. Repeating elements (black box) were excluded from bait design. The three
CCDC6-RET fusion sequences are starred.
Nucleic Acids Research, 2010, Vol.38, No. 20 6991Figure 4. Genomic structure of FGFR1OP2-FGFR1 in KG-1 cells. (A) Four sequences (labeled with ‘FVJ056W02’ barcodes) were recovered that
mapped to the forward strand of exon 9 (red) and the reverse complement (rc) of the intron between exons 9 and 10 (blue) within FGFR1, indicating
a possible fusion. The fourth sequence contains an extra C across the fusion point. This may be due to a 454 sequencing artifact, as it was not
detected by direct sequencing. (B) The fusion was conﬁrmed only in KG-1 cells by PCR using breakpoint-spanning primers. The FGFR1 regions
from exon 9 (ex9) and intron 9-10 (in9/10) correspond to the areas disrupted as a consequence of the fusion. (C) Direct sequencing chromatograms of
the PCR product containing the fusion. The corresponding 12nt are underlined in A.( D) Schematic of the genomic structure of FGFR1OP2-FGFR1.
Primers used for long-range PCR and 50RACE are indicated with arrows. The GXGXXG-encoding exon is marked with an asterisk. (E) 454
sequences from captured KG-1 DNA (black) were mapped to the genome with the custom 120-mer baits (green), and the target region for FGFR1
(red). The location of the gene within the chromosome is denoted by a vertical red bar. Repeating elements (black boxes) were excluded from bait
design. The four sequences containing the FGFR1 rearrangement (starred) were mapped to the region with highest homology.
6992 Nucleic Acids Research, 2010, Vol.38, No. 20the pool of KG-1 454 sequences. The four sequences con-
taining this fusion mapped to the forward strand of a
portion of exon 9 and to the reverse complement of a
portion of the intron between exons 9 and 10, suggesting
an FGFR1 rearrangement occurring 50 to exon 10
(Figure 4D). However, from the 454 reads alone, we
were not able to deduce the exact upstream partner.
Subsequent application of 50–RACE using primers
speciﬁc to exons 10 and 11 of FGFR1 found only the
FGFR2OP1-FGFR1 fusion previously reported (data not
shown).
To elucidate further how the recovered 454 fusion se-
quences were related to the FGFR2OP1-FGFR1 alter-
ation, we performed sequencing of long-range PCR
products obtained from ampliﬁcation of the DNA
sequence between exon 4 of FGFR1OP2 and exon 10 of
FGFR1. This  5kb region contained sequences that
matched 100% to our 454 fusion reads, but we found
that the genomic structure was much more complex,
involving elements from intron 4-5 of FGFR1OP2, the
inverted truncated exon 9, and intron 9-10 of FGFR1
(Figure 4D). Collectively, these data illustrate two
points. First, data from our capture-sequence approach
suggested a breakpoint occurring at a speciﬁc region in
the kinase and were sufﬁcient to allow us to ﬁnd readily
the upstream partner using 50-RACE. Second, fusion
breakpoints can be more complex than just the juxtapos-
ition of two intronic elements from two different genes.
Approximately 88% of the FGFR1 capture region was
covered with baits (Figure 4E; Supplementary Table S2),
and FGFR1-containing KG-1 sequences were enriched
1922-fold with an 11-fold average coverage of the target
region. Simultaneous mapping of the baits and sequences
revealed a similar pattern to that observed for TPC-1
reads (Figure 4E). A large repeating region between
exons 9 and 10 contained no sequence coverage due to
the lack of baits. The four FGFR1 sequences containing
the rearrangement could have been captured by 8 baits.
Analysis of NSCLC control cell lines
Three well-characterized lung cancer cell lines without
known fusions were also included as controls:
NCI-H820, harboring mutant EGFR (exon 19 deletion,
T790M) and ampliﬁcation of MET (33), NCI-H1703,
with ampliﬁcation of PDGFR  (9) and NCI-H3255, con-
taining ampliﬁed mutant EGFR (L858R) (34). Analysis of
the sequences from H820, H3255 and H1703 identiﬁed 8,
12 and 24 candidate fusions, respectively (data not
shown). None of the fusions were conﬁrmed by PCR
with breakpoint spanning primers. Enrichment of
TK-containing sequences for these lines was similar to
that of the fusion lines (data not shown). These data are
consistent with a modest false positive rate also observed
with other fusion discovery efforts that have used 454
sequencing (13,17). We hypothesize that the false
positive sequences are likely an artifact of the ligation
step used to add sequencing adaptors onto DNA frag-
ments. We expect this number to decrease in future iter-
ations of the method as reﬁnements are made to the
sequencing preparation steps.
DISCUSSION
The success of the ABL TK inhibitor, imatinib, in CML
patients with BCR-ABL translocations and of the new
ALK TK inhibitor in lung cancer patients with
EML4-ALK fusions illustrates that cancer-driving TK
fusions serve as excellent therapeutic targets. Exactly
how many TK fusions exist in cancers, though, is currently
unknown, because identiﬁcation of TK fusions has trad-
itionally required highly laborious techniques. As an
example, BCR-ABL rearrangements were identiﬁed
using conventional karyotyping, which ﬁrst revealed the
Philadelphia chromosome (35), followed by identiﬁcation
of the t(9;22) translocation (36), and eventual cloning of
the ABL translocation (37). EML4-ALK fusions were dis-
covered by (i) application of a tumor-derived cDNA ex-
pression library to a mouse 3T3 ﬁbroblast focus formation
assay (10) and (ii) immunoafﬁnity phosphoproteomic
proﬁling by mass spectrometry (9).
Based upon an in silico analysis, we found that known
TK rearrangements display conserved fusion point
properties that might make them amenable to systematic
screening using new technologies. This analysis led us to
design a novel DNA-based approach to identify TK
fusions in a selectively targeted high-throughput manner.
Regions of genomic DNA likely to be involved in TK
fusion events are captured by hybridization to custom
designed RNA baits. Captured DNA is eluted and
sequenced using next-generation 454 sequencing. We
chose 454 sequencing over other deep sequencing plat-
forms speciﬁcally because of its ability to achieve longer
read lengths ( 200nt; Table 1, Supplementary Figure S1),
which could facilitate direct identiﬁcation of fusion points
that lie far upstream from the captured region
(Figure 3A). Novel computational algorithms then allow
for rapid identiﬁcation of candidate fusions, which are
validated by simple direct PCR or 50-RACE methods.
As proof that this approach is feasible and robust, we
used it to map previously unknown genomic breakpoints
in two human cancer cell lines (including both solid and
hematologic malignancies) harboring fusions with RET
and FGFR1, respectively, using only 1.5mg of DNA from
each line. In both cases, we identiﬁed novel genomic fusion
sequences and structures of the breakpoints. Importantly,
having established workﬂow for the platform, identiﬁca-
tion of candidate fusion sequences in a given tumor sample
could theoretically be completed in  2–3 weeks, encom-
passing DNA isolation and preparation, DNA capture,
454 sequencing and computational analysis.
The advent of high throughput next-generation
sequencing technologies has recently facilitated the discov-
ery of multiple types of translocation events in cancer cells
(Table 2). One approach involves whole genome
sequencing, which requires adequate starting material
and large numbers of sequences for adequate coverage.
As a result, genome-wide next-generation sequencing
efforts are often coupled with copy number and karyotype
data to prioritize regions where translocations may have
occurred (15,16). This strategy requires complex compu-
tational algorithms that integrate sequencing and chromo-
somal analyses.
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have been used to detect multiple types of fusion events
(Table 2). These include whole transcriptome sequencing
(13,14,18), and screening for disparate levels of expression
between 50 and 30-ends of kinase genes on exon arrays
(with expression higher in the 30-end) (38). Whole tran-
scriptome sequencing provides meaningful expression
level data while eliminating background from non-coding
genomic elements. However, this approach also requires
analysis of a large number of sequences due to the abun-
dance of housekeeping, ribosomal and mitochondrial
transcripts, and is often coupled with copy number data
as well. Recently, selective capture of 467 cancer related
genes was applied to a cDNA library, and analysis of the
subsequent massively parallel sequencing found multiple
fusion events, demonstrating the use of this capture-
sequence approach to detect translocations (20).
However, the sequencing analysis demands are high.
Most importantly, the sample requirements (20mg DNA,
up to 100mg of total RNA, or 1mg of mRNA) for the
above DNA- and RNA-based platforms are prohibitive
for most standard patient samples, thus limiting the
broad utility of these approaches. A DNA-based capture
platform avoids the use of RNA, which is inherently less
stable than DNA and more difﬁcult to extract without
degradation from clinical specimens.
While the fusion events identiﬁed through other
methods are important for understanding the pathogen-
esis of cancer cells, their therapeutic potential remains
unknown. Therefore, we focused speciﬁcally on identiﬁca-
tion of TK fusions which can be potentially targeted with
speciﬁc kinase inhibitors. Based on the genomic properties
of known TK fusions, we designed a highly focused
capture platform that should detect 92% of known TK
fusions. From  160 000 sequences, we recovered only one
sequence that fell within the housekeeping gene category.
Furthermore, high density SNP analysis (Affymetrix 6.0
arrays) of DNA from both TPC-1 and KG-1 cells revealed
that only the CCDC6-RET fusion was apparent from copy
number studies (data not shown). Although this approach
was validated using only cell line DNA, we do not antici-
pate problems using DNA from more heterogeneous
tumor samples. Given the increased efﬁciency of capture
methods developed by Agilent since our pilot study, we
expect a greater percentage of the  100000 recovered se-
quences from each run to map back to our target regions.
Even from this pilot study, we know that fusions are still
detectable with as few as  13000 sequences (the number
of TPC-1 sequences that mapped back to kinase targets;
Table 1).
While our capture-sequence platform has distinct ad-
vantages, there are some limitations. First, if fusions
occur outside of the targeted regions or within large re-
petitive elements, they would not be identiﬁed with this
method. However, based on our in silico analysis, the
majority of fusions should occur within the targeted
regions, and our original design attempted to balance
feasibility with the effort required to sift through
hundreds of thousands of wild-type sequences. Other
groups have been unable to detect a conserved motif at
translocation breakpoints (16), indicating that fusions
may occur in broadly deﬁned regions versus at speciﬁc
sequence motifs. Many of the genomic fusion sequences
that we have analyzed occur outside of repeat elements,
and those that occur within masked regions are still
amenable to capture due to the length of the recovered
sequences extending into regions without baits
(Chmielecki and Pao, unpublished observations).
Second, we detected a modest number of false positive
fusion events ( 0.025% of total sequences). However,
this is a common problem for all fusion discovery plat-
forms (with DNA and RNA), and the number of candi-
date fusions identiﬁed with our method is comparable to
other similar methods. Third, the percentage of total se-
quences mapping to our baits is much lower than similar
capture reports (22). However, our study used an early
‘beta’ version of the SureSelect technology, and capture
has improved signiﬁcantly since the ofﬁcial launch of the
product. Additionally, SureSelect was not optimized for
454 sequencing at the time of this study. Fourth, other
types of fusion events (e.g. ETS gene fusions) were
omitted from our design, because targeted therapies for
these types of translocations have yet to be developed.
However, in theory, a similar capture platform could be
designed based on the genomic properties of transcription
factor fusions. Fifth, gaps in sequence coverage may be
unavoidable due to deletions in tumor cell DNA,
GC-richness, and regions not amenable to PCR
Table 2. Comparison of deep sequencing-based fusion discovery efforts
Method Focus Sequencer Starting material Length of reads Total no. of reads
Genome wide paired end Somatic rearrangements Illumina GA 5mg gDNA 29–36nt 36.2M
Transcriptome sequencing All genes fusions Illumina GA with 454 50mg total RNA 36nt–230nt 66.9M/500–800K
Transcriptome paired end All genes fusions Illumina GA 1mg mRNA 50–100nt 16.9–25M
Targeted RNA-seq Cancer-related genes Illumina GA 3mg mRNA 76nt 8
TK capture sequence TK fusions 454 1.5kg gDNA 220nt 60–100K
Multiple studies have focused on fusion discovery within cancer samples and cell lines. While the recovery of known and unknown fusions has been
highest in transcriptome-based approaches, the amount of starting material is often limiting for most patient samples. Furthermore, the number of
reads required to detect conﬁdently fusions presents ﬁnancial and computational challenges. This study (bold) outlines a strategy that uses minimal
amounts of genomic DNA and requires analysis of fewer sequence reads. However, sequencing strategies are evolving rapidly, and additional
improvements are expected in starting material requirements and computational algorithms for the analysis of large quantities of sequences. See
Discussion text for references. gDNA=genomic DNA; nt=nucleotides; M=million; K=thousand
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project where sequence gaps across regions are not the
same for each sample (see custom UCSC Genome
Browser). Finally, we note that strategies for fusion iden-
tiﬁcation (Table 2) are rapidly evolving, and this platform
represents just one approach towards kinase fusion dis-
covery. The capture strategy we designed could theoretic-
ally be paired with any sequencing technology (e.g. SOLiD
and Illumina GA, for which SureSelect is already
optimized). As computational algorithms are reﬁned
further for such applications, these different sequencing
approaches may represent alternatives that offer greater
cost-effective analysis.
In the future, we plan to increase bait coverage from 2x
to 5x, allowing for greater enrichment of our target
regions. Baits with poor capture efﬁciency are also being
redesigned to better capture some genomic regions. One
redesign strategy includes creating baits against the
opposite DNA strand in the event that the opposite
sequence is more amenable to capture. Recovered se-
quences will then be sequenced using the 454 Titanium
platform, which allows for much longer reads ( 500bp).
This longer read length will enhance sequence coverage
across the target regions and allow for sequencing into
areas not covered directly with baits. Additionally, the
improved bait design paired with longer sequencing
reads should further decrease the number of false
positive candidate fusions by mapping more precisely
the recovered sequences.
In summary, we have devised a DNA-based platform
using highly focused targeted capture and 454 sequencing
for rapid and systematic discovery of TK fusions in
cancers. Our data demonstrate that this novel method is
feasible, rapid and applicable to routine tumor samples.
Using this platform, we identiﬁed for the ﬁrst time
genomic fusion sequences of two TK fusion proteins
(CCDC6-RET and FGFR1OP2-FGFR1), including the
unique genomic structure of FGFR1OP2-FGFR1. We
now plan to screen tumor sets for novel kinase rearrange-
ments. To extend further its utility, we will also determine
if this method can be used on DNA extracted from
formalin-ﬁxed parafﬁn-embedded tissue. Ideally, we
hope to accelerate discovery of multiple novel TK
fusions and facilitate clinical development of targeted
anti-cancer therapies.
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Supplementary Data are available at NAR Online.
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